OncoMatch/Clinical Trials/NCT07281976
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
Is NCT07281976 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including LBL-024 for and albumin-bound Paclitaxel for triple negative breast cancer.
Treatment: LBL-024 for · albumin-bound Paclitaxel · Toripalimab — This trial is an open-label, multicenter phase Ib/II clinical study to evaluate the efficacy and safety of LBL-024 monotherapy or in combination with albumin-bound paclitaxel in patients with recurrent or metastatic triple negative breast cancer(TNBC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: immunomodulatory drug
Use of immunomodulatory drugs within 2 weeks prior to first dose of study drug.
Cannot have received: live vaccination
Patients who received live vaccination within 4 weeks before the first dose of study drug or who are scheduled to receive live vaccination during the study treatment period and within 4 weeks after the last dose.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify